Arrhythmia
Conditions
Brief summary
The use of propafenone and propranolol in children during clinical treatment was depending mostly on experience. Besides, there was no recommended dose for children in drug instruction. Therefore, the investigators' aim is to study the pharmacokinetics and pharmacodynamics in children.
Interventions
DRUGPropafenone and Propranolol
Propafenone Hydrochloride Tablets, 100-200mg, 1 or 2 times per day; Propranolol Hydrochloride Sustained-Release Capsules, 40mg, 1 times per day
Sponsors
Shandong University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged ≤18years. Parental written consent to participate in the study. Patients treat with Propafenone and Propranolol
Exclusion criteria
* Patients can not complete the research; Abnormal hepatic and renal function; Patient is allergic to propafenone; There are conditions that researchers do not consider it appropriate to join the research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ventricular premature beats of 24 hours | From date of randomization until the date of discharge, assessed up to 12 months | frequency of Ventricular premature beats of 24 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| P-R interval | From date of randomization until the date of discharge, assessed up to 12 months | P-R interval time |
| QT interval | From date of randomization until the date of discharge, assessed up to 12 months | QT interval time |
Countries
China
Outcome results
None listed